



HAL
open science

Clostridioides difficile peptidoglycan modifications

Héloïse Coullon, Thomas Candela

► **To cite this version:**

Héloïse Coullon, Thomas Candela. Clostridioides difficile peptidoglycan modifications. Current Opinion in Microbiology, 2022, 65, pp.156-161. 10.1016/j.mib.2021.11.010 . hal-03933803

HAL Id: hal-03933803

<https://hal.inrae.fr/hal-03933803v1>

Submitted on 1 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2
3
4
5
6
7
8
9

Clostridioides difficile peptidoglycan modifications

Héloïse Coullon^{1,2} and Thomas Candela¹

1 Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas

2 Division of Infectious Diseases, Dept. of Medicine; Washington University School of Medicine; St. Louis, MO, USA.

Corresponding author: Candela, Thomas (thomas.candela@universite-paris-saclay.fr)

10 Abstract

11 The cortex and peptidoglycan of *Clostridioides difficile* have been poorly investigated. This last decade,
12 the interest increased because these two structures are highly modified and these modifications may
13 be involved in antimicrobial resistance. For example, *C. difficile* peptidoglycan deacetylation was
14 recently reported to be involved in lysozyme resistance. Modifications may also be important for spore
15 cortex synthesis or spore germination, which is essential in *C. difficile* pathogenesis. As such, the
16 enzymes responsible for modifications of the peptidoglycan and/or cortex could be new drug target
17 candidates or used as anti-*C. difficile* agents, as seen for the CD11 autolysin. In this review, we focused
18 on *C. difficile* peptidoglycan and cortex and compared their structures with those of other well studied
19 bacteria.

20

21 Introduction

22 Peptidoglycan is specific and unique to bacteria [1]. It surrounds bacteria and is necessary for bacterial
23 growth. In *C. difficile*, this structure is found as a part of the vegetative cell wall but also in the cortex,
24 which is a peptidoglycan-like structure found in the spore [2]. Many peptidoglycan modifications are
25 reported and some may be crucial for the bacterial survival and way of life [3]. In this review, we will
26 focus on the *C. difficile* peptidoglycan and cortex structures and their modifications in comparison with
27 those of other well-studied bacteria.

28

29 Peptidoglycan structure

30 The amino acids found in the pentapeptide stem of *C. difficile* peptidoglycan are similar to that of gram
31 negative or *Bacillus* genus bacteria, including D-Alanine, L-Alanine, D-Glutamate and meso
32 diaminopimelic acid (A₂pm) [4] (Figure 1A). In addition to these amino acids, several new amino acids
33 such as phenylalanine, lysine, valine or modified alanine were identified in low amounts in the
34 mucopeptides of the 630Δ*erm* strain using LC–high-resolution mass spectrometry [5]. Aside from the
35 composition of the pentapeptide stem, the bacterial peptidoglycan of *C. difficile* has several highly
36 unique characteristics. Amongst these characteristics, it contains a majority of A₂pm³→ A₂pm³ cross-
37 links (2,6 diaminopimelic acid linked in position 3 of the peptide of the peptidoglycan) instead of D-
38 Ala→ A₂pm³ cross-links found in the majority of bacteria (Figure 1A) [6]. Through a combination of
39 genetic knock-out studies and characterization of recombinant proteins, three proteins have been
40 shown to be L,D-transpeptidases with partially redundant functions leading to the formation of
41 A₂pm³→ A₂pm³ cross-links [7]. However, discrepancies between these proteins could hint at
42 differences in localization, substrate specificity, antibiotic sensitivity or even essentiality. Indeed,
43 inactivation of *ldt_{cd1}* and *ldt_{cd2}* lead to a decrease in the abundance of A₂pm³→ A₂pm³ cross-links in
44 peptidoglycan. In contrast, no mutant could be generated for *ldt_{cd3}*, suggesting that *ldt_{cd3}* is essential
45 [7]. Recombinant proteins of *Ldt_{cd1}* and *Ldt_{cd2}* were found to be the targets of carbapenems, while this
46 was not seen for the recombinant protein of *Ldt_{cd3}* [7]. Incubation of recombinant proteins with
47 disaccharide-tetrapeptide revealed that *Ldt_{cd2}* and *Ldt_{cd3}* display L,D-transpeptidase and L,D-
48 carboxypeptidase activities. In contrast, the *Ldt_{cd1}* recombinant protein displayed only L,D
49 carboxypeptidase activity in these experimental conditions [7]. Finally, it is important to note that the
50 L,D-transpeptidase encoded by *ldt_{cd2}*, Cpw22, has recently been studied and shown to be involved in
51 cell wall integrity and viability in the R20291 strain [8].

52

53 Peptidoglycan deacetylation

54 The second particularity of the *C. difficile* peptidoglycan is the high *N*-deacetylation of the glucosamine
55 (93 to 97.5% according to the studies) [5,9,10]. Among 12 potential *N*-deacetylases encoded in the
56 genome of *C. difficile*, at least two are involved in the peptidoglycan *N*-deacetylation and lysozyme
57 resistance. These enzymes, PdaV and PgdA, act in synergy and are regulated by the extracytoplasmic
58 function σ^V (sigma factor V) [5,9,10]. *pdaV* expression is fully dependent on σ^V whereas *pgdA* is still
59 expressed in a *csfV* mutant (*csfV* encodes σ^V) suggesting a difference of regulation for both genes. Each
60 individual mutant, *pgdA* or *csfV*, is slightly more sensitive to lysozyme than the parental strain (4-fold
61 in the 630Δ*erm* and 2-fold and 8-fold respectively in the R20291 [5,10]). In contrast, the double mutant
62 is more than 130-fold more sensitive to lysozyme in the 630Δ*erm* strain and 1000-fold in the R20291
63 strain [5,9]. In other pathogenic bacteria such as *Streptococcus pneumoniae* or *Listeria*
64 *monocytogenes*, the absence of peptidoglycan *N*-deacetylation altered the virulence [11,12]. In

65 contrast, *in vivo* virulence studies done in *C. difficile* showed that although the intestinal colonization
66 is lower for the double mutant $\Delta pgdA\ csfV$ compared to the parental strain, the double mutant is more
67 virulent than the parental strain [5]. A possible explanation for this observation, that need to be further
68 investigated, is that the increased lysozyme sensitivity of the double mutant, shown *in vitro*, could lead
69 to a stronger bacterial lysis during *in vivo* infection. This could facilitate the release of toxins TcdA and
70 TcdB [13,14], ultimately leading to a higher mortality of the host.

71

72 Peptidoglycan modifications in the presence of vancomycin

73 Peptidoglycan modifications may be also involved in antibiotic resistance [15]. Indeed, bacterial
74 resistance to vancomycin has been linked to the presence of a *van* gene cluster [16]. While 74% of
75 *C. difficile* strains possess a *vanG_{cd}* gene cluster [17,18], only a few clinical strains have been found to
76 harbor a vancomycin resistance [19]. The *vanG_{cd}* gene cluster is composed of two operons: a regulation
77 operon (*vanR* and *vanS*) and a resistance operon (*vanG*, *vanXY* and *vanT*). The regulation operon is
78 constitutively expressed, whereas the resistance operon is induced by the presence of vancomycin
79 through the two-component system VanS-VanR. In the presence of vancomycin, the peptidoglycan
80 precursors are modified and close to 40% of them are UDP-MurNac-pentapeptide[D-Ser] instead of
81 the natural peptidoglycan precursor UDP-MurNac-pentapeptide[D-Ala] [17]. This low rate of modified
82 precursors may lead to the slight change in vancomycin susceptibility between the *vanG* or *vanR*
83 mutants (MIC 0.75 mg L⁻¹) and the parental strain (MIC 1.5 mg L⁻¹). The lack of resistance and low rate
84 of modified precursor UDP-MurNac-pentapeptide[D-Ser] may be explained by the absence of D,D-
85 carboxypeptidase activity of VanXY and the fact that MurF has a preferential use of lipid II ending with
86 D-Ala-D-Ala instead of D-Ala-D-Ser [17]. In addition, in the presence of vancomycin, Ammam *et al.*
87 reported amidation of a subset of peptidoglycan precursors [20]. This modification was only found in
88 the presence of vancomycin and was independent from the VanS-VanR two-component system.
89 Intriguingly, when the asparagine synthetase *asnB* was overexpressed, more than 90% of the
90 peptidoglycan precursors were amidated, but the growth or morphology of the strain was similar to
91 that of the parental strain [20]. In contrast, the overexpression of *asnB* led to a decrease of the
92 vancomycin MIC from 2-3 to 1-1.5 mg L⁻¹ [20]. Finally, Shen *et al.* recently showed that a weak
93 expression of the resistance operon is involved in the lack of vancomycin resistance [19]. Indeed,
94 punctual mutations in *vanS* or *vanR* may increase the expression of the resistance operon, leading to
95 an increase of the MIC from 4 to 16 mg L⁻¹. In addition, Pu *et al.* identified a transferable plasmid (pX18-
96 498) that is found in clinical strains associated with vancomycin treatment failure in CDI patients [21].
97 This plasmid may result in decreased susceptibility to vancomycin. The combination of such a plasmid
98 with mutations in *vanR* and/or *vanS* may result in increasing rates of vancomycin resistance in *C.*
99 *difficile* strains.

100

101 Peptidoglycan autolysins

102 Autolysins are enzymes that maturate the peptidoglycan and are be involved in toxins release [22].
103 Several were recently predicted in *C. difficile* [23]. Among them, the N-acetylglucosaminidase Acd was
104 studied using *B. subtilis* peptidoglycan (highly acetylated on its glucosamine) [24]. It would be worth
105 to know whether this enzyme is also able to act on deacetylated muropeptides since *C. difficile*
106 peptidoglycan is highly deacetylated. A second autolysin, Cwp19, is a lytic transglycosidase that cleaves
107 the peptidoglycan between the N-acetyl muramic acid and the N-acetyl glucosamine [13,25,26].
108 Interestingly, it was shown that the toxins, TcdA and TcdB, were released due to the autolysis induced
109 by Cwp19, in a process that appears media specific [26]. This autolysin is expressed during the active

110 phase of growth (mainly up to 24h of growth), but its activity is detected during the late stationary
111 phase of growth (from 24h). The hypothesis behind this apparent inconsistency is that a secondary
112 polymer like the PSII or the LTA could modulate its autolytic activity. However, CWP proteins, including
113 Cwp19, are suggested to be placed at the top of the PSII [27] and therefore should be resistant to the
114 shielding-like activity proposed. Two N-acetylmuramoyl-L-alanine amidases, CD11 and CDG, are
115 produced by *C. difficile* prophages and were identified as clinical candidates to target *C. difficile*
116 infection [28]. These enzymes may have a role in the peptidoglycan maturation. However, it was later
117 shown that CD11 is able to kill *C. difficile* bacteria in PBS, but is mostly inactivated by the wall teichoic
118 acids [28]. CwIA is a peptidoglycan hydrolase described in the 630 Δ *erm* (CD630_11350) and in the
119 R20291 (Cwl0971) strains [29,30]. This endopeptidase has three SH3_3 domains (also named SH3_b
120 [31]) and a NLPC/60 super family catalytic domain. CwIA cleaves the stem peptide of the peptidoglycan
121 between the γ -D-Glu and mDAP. CwIA is predominantly found at the septum, and in its absence, *C.*
122 *difficile* has a cell separation defect. In the R20291 strain, *cwIA* was found to be mainly expressed in
123 the exponential phase of growth and in a lesser extent during the stationary phase. Recent work has
124 shown that CwIA is in fact controlled by the Serine/Threonine kinases PrkC and CD630_21480 [29,32].
125 The proposed model is that PrkC is able to phosphorylate CwIA, which leads to cytoplasmic localization
126 of CwIA. In contrast, unphosphorylated CwIA is exported in the cell wall where it is able to cleave the
127 peptidoglycan [29]. This is a particular regulation that was not reported previously.

128

129 Spore cortex

130 The composition and structure of *C. difficile* spore cortex has recently been extensively characterized
131 [33] (Figure 1B). It consists in muropeptides that are predominantly found as monomers
132 (approximately 90% of muropeptides) and a minority found as dimers, leading to a very low cross-
133 linking index (< 5%). Muramic- δ -lactams were detected on 24% of the muropeptides, in contrast with
134 *B. subtilis* [34] or *C. perfringens* [35] where 50% of muropeptides contained muramic- δ -lactams. Unlike
135 species such as *B. subtilis* where a single PdaA N-deacetylase is involved in muramic- δ -lactam synthesis
136 [36], two N-deacetylases were found to be involved in the muramic- δ -lactam synthesis in *C. difficile*:
137 PdaA1 and PdaA2 (CD630_14300 and CD630_27190 respectively) [33]. These two enzymes are forming
138 the δ -lactams after the processing of muramic acid and its stem peptide by GerS and CwID [37,38]. A
139 mutant of *pdaA1* and *pdaA2* exhibits a decreased sporulation, a decreased heat resistance, delayed
140 virulence in a hamster infection model, and an altered germination [33]. In contrast, *B. subtilis* cannot
141 germinate if the muropeptides lack muramic- δ -lactams [39]. Interestingly, enzymes such as the cortex
142 lytic enzyme SleC are sensitive to the presence of δ -lactams (see *C. difficile* spore germination section)
143 [40-42]. Another distinctive characteristic of the *C. difficile* cortex is that 22% of the muropeptides in
144 the cortex were not substituted, in contrast with *B. subtilis* where most of them were substituted with
145 L-alanine. Finally, 55% to 61% of the muropeptides were N-deacetylated in the cortex of *C. difficile*
146 630 Δ *erm* whereas no or very low N-deacetylation was observed in the cortex of *B. subtilis* or
147 *C. perfringens* (10%) [33-35]. This high percentage of N-deacetylation in the cortex of *C. difficile* may
148 be driven by the high number of N-deacetylases. One of the enzymes potentially involved in the spore
149 cortex N-deacetylation is PgdB (CD630_32570) [33]. Indeed, *pgdB* was poorly expressed during the
150 bacterial growth and is under control of σ^E factor [33,43]. Moreover, a slight decrease in glucosamine
151 N-deacetylation (5%) of the spore cortex was observed in the Δ *pgdB* mutant [5]. This suggest that other
152 N-deacetylases are involved in the N-deacetylation of the spore cortex in *C. difficile*. Spore cortex is
153 synthesized by both the mother cell and the forespore [2,44]. During the engulfment stage of
154 sporulation, the bacterial peptidoglycan is separated from the spore cortex by specific autolysins such
155 as SpoIID and SpoIIP [37,45,46] (see *C. difficile* spore assembly section), and this process relies on the
156 structural differences between bacterial peptidoglycan and spore cortex. Since very little is known

157 about N-deacetylation in the spore cortex, the impact of this modification has to be further
158 investigated to fully understand its contribution to the sporulation and germination processes.

159

160 Conclusions

161 Some advances have been highlighted in studying the peptidoglycan and cortex of *C. difficile* in the last
162 decade. A deeper study of the peptidoglycan structure, biogenesis, recycling and degradation will allow
163 a better understanding of the role of the *C. difficile* peptidoglycan in the toxin release and in the
164 antibiotic and antimicrobial resistances. Finally, the recent analysis of the cortex structure will allow a
165 better understanding of the germination process through its hydrolysis.

166

167 Funding

168 H. C. was supported by Allocations de recherche du Ministère de la Recherche (MNERT).

169

170 Declaration of interest

171 None

172

173 References:

174 * Of special interest

175 ** Of outstanding interest

176

177 1. Pazos M, Peters K: **Peptidoglycan**. *Subcell Biochem* 2019, **92**:127-168.

178 2. Popham DL, Bernhards CB: **Spore Peptidoglycan**. *Microbiol Spectr* 2015, **3**.

179 3. Vollmer W, Blanot D, de Pedro MA: **Peptidoglycan structure and architecture**. *FEMS Microbiol Rev*
180 2008, **32**:149-167.

181 4. * Peltier J, Courtin P, El Meouche I, Lemée L, Chapot-Chartier MP, Pons JL: ***Clostridium difficile* has**
182 **an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation**
183 **and mainly 3-3 cross-links**. *J Biol Chem* 2011, **286**:29053-29062.

184 This publication is the first to report the structure of *C. difficile* bacterial peptidoglycan and further
185 investigates the structural modifications observed in *ldt_{Cd1}* and *ldt_{Cd2}* mutants.

186

187 5. ** Coullon H, Rifflet A, Wheeler R, Janoir C, Boneca IG, Candela T: **Peptidoglycan analysis reveals**
188 **that synergistic deacetylase activity in vegetative *Clostridium difficile* impacts the host**
189 **response**. *J Biol Chem* 2020, **295**:16785-16796.

190 This publication provides additional extensive characterization of *C. difficile* peptidoglycan using
191 state-of-the-art analyses, and establishes the respective contributions of N-deacetylases in
192 the high level of glucosamine N-deacetylation found in *C. difficile*

193

194 6. Lin H, Lin L, Du Y, Gao J, Yang C, Wang W: **Biodistributions of l,d-Transpeptidases in Gut**
195 **Microbiota Revealed by *In Vivo* Labeling with Peptidoglycan Analogs**. *ACS Chem Biol* 2021,
196 **16**:1164-1171.

197 7. * Sütterlin L, Edoos Z, Hugonnet JE, Mainardi JL, Arthur M: **Peptidoglycan Cross-Linking Activity of**
198 **l,d-Transpeptidases from *Clostridium difficile* and Inactivation of These Enzymes by β-**
199 **Lactams**. *Antimicrob Agents Chemother* 2018, **62**.

200 This publication investigates the role of *Ldt_{Cd1}*, *Ldt_{Cd2}* and *Ldt_{Cd3}* in the formation of 3-3 cross-links in
201 the peptidoglycan of *C. difficile*.

202

203 8. Zhu D, Bullock J, He Y, Sun X: **Cwp22, a novel peptidoglycan cross-linking enzyme, plays**
204 **pleiotropic roles in *Clostridioides difficile***. *Environ Microbiol* 2019, **21**:3076-3090.

205 9. Ho TD, Williams KB, Chen Y, Helm RF, Popham DL, Ellermeier CD: ***Clostridium difficile***
206 **extracytoplasmic function σ factor σ_V regulates lysozyme resistance and is necessary for**
207 **pathogenesis in the hamster model of infection**. *Infect Immun* 2014, **82**:2345-2355.

208 10. Kaus GM, Snyder LF, Müh U, Flores MJ, Popham DL, Ellermeier CD: **Lysozyme Resistance in**
209 ***Clostridioides difficile* Is Dependent on Two Peptidoglycan Deacetylases**. *J Bacteriol* 2020,
210 **202**.

211 11. Boneca IG, Dussurget O, Cabanes D, Nahori MA, Sousa S, Lecuit M, Psylinakis E, Bouriotis V, Hugot
212 JP, Giovannini M, et al.: **A critical role for peptidoglycan N-deacetylation in *Listeria* evasion**
213 **from the host innate immune system**. *Proc Natl Acad Sci U S A* 2007, **104**:997-1002.

214 12. Vollmer W, Tomasz A: **Peptidoglycan N-acetylglucosamine deacetylase, a putative virulence**
215 **factor in *Streptococcus pneumoniae***. *Infect Immun* 2002, **70**:7176-7178.

216 13. El Meouche I, Peltier J: **Toxin release mediated by the novel autolysin Cwp19 in *Clostridium***
217 ***difficile***. *Microb Cell* 2018, **5**:421-423.


218 14. Govind R, Dupuy B: **Secretion of *Clostridium difficile* toxins A and B requires the holin-like**
219 **protein TcdE**. *PLoS Pathog* 2012, **8**:e1002727.

220 15. Rajagopal M, Walker S: **Envelope Structures of Gram-Positive Bacteria**. *Curr Top Microbiol*
221 *Immunol* 2017, **404**:1-44.

- 222 16. Courvalin P: **Vancomycin resistance in gram-positive cocci.** *Clin Infect Dis* 2006, **42 Suppl 1**:S25-
223 34.
- 224 17. Ammam F, Meziane-Cherif D, Mengin-Lecreux D, Blanot D, Patin D, Boneca IG, Courvalin P,
225 Lambert T, Candela T: **The functional *vanG_{cd}* cluster of *Clostridium difficile* does not confer**
226 **vancomycin resistance.** *Mol Microbiol* 2013, **89**:612-625.
- 227 18. Peltier J, Courtin P, El Meouche I, Catel-Ferreira M, Chapot-Chartier MP, Lemée L, Pons JL:
228 **Genomic and expression analysis of the *vanG*-like gene cluster of *Clostridium difficile*.**
229 *Microbiology (Reading)* 2013, **159**:1510-1520.
- 230 19. * Shen WJ, Deshpande A, Hevener KE, Endres BT, Garey KW, Palmer KL, Hurdle JG: **Constitutive**
231 **expression of the cryptic *vanG_{cd}* operon promotes vancomycin resistance in *Clostridioides***
232 ***difficile* clinical isolates.** *J Antimicrob Chemother* 2020, **75**:859-867.
- 233 This publication highlights the role of the level of expression of *vanG_{cd}* cluster in the vancomycin
234 resistance of *C. difficile*.
- 235
- 236 20. Ammam F, Patin D, Coullon H, Blanot D, Lambert T, Mengin-Lecreux D, Candela T: **AsnB is**
237 **responsible for peptidoglycan precursor amidation in *Clostridium difficile* in the presence**
238 **of vancomycin.** *Microbiology (Reading)* 2020, **166**:567-578.
- 239 21. * Pu M, Cho JM, Cunningham SA, Behera GK, Becker S, Amjad T, Greenwood-Quaintance KE,
240 Mendes-Soares H, Jones-Hall Y, Jeraldo PR, et al.: **Plasmid Acquisition Alters Vancomycin**
241 **Susceptibility in *Clostridioides difficile*.** *Gastroenterology* 2021, **160**:941-945 e948.
- 242 This publication highlights the role of *C. difficile* plasmids in the peptidoglycan modifications and
243 vancomycin resistance.
- 244
- 245 22. Elahi M, Nakayama-Imaohji H, Hashimoto M, Tada A, Yamasaki H, Nagao T, Kuwahara T: **The**
246 **Human Gut Microbe *Bacteroides thetaiotaomicron* Suppresses Toxin Release from**
247 ***Clostridium difficile* by Inhibiting Autolysis.** *Antibiotics (Basel)* 2021, **10**.
- 248 23. Mitchell SJ, Verma D, Griswold KE, Bailey-Kellogg C: **Building blocks and blueprints for bacterial**
249 **autolysins.** *PLoS Comput Biol* 2021, **17**:e1008889.
- 250 24. Dhalluin A, Bourgeois I, Pestel-Caron M, Camiade E, Raux G, Courtin P, Chapot-Chartier MP, Pons
251 JL: **Acd, a peptidoglycan hydrolase of *Clostridium difficile* with N-acetylglucosaminidase**
252 **activity.** *Microbiology (Reading)* 2005, **151**:2343-2351.
- 253 25. Bradshaw WJ, Kirby JM, Roberts AK, Shone CC, Acharya KR: **The molecular structure of the**
254 **glycoside hydrolase domain of Cwp19 from *Clostridium difficile*.** *FEBS J* 2017, **284**:4343-
255 4357.
- 256 26. Wydau-Dematteis S, El Meouche I, Courtin P, Hamiot A, Lai-Kuen R, Saubaméa B, Fenaille F, Butel
257 MJ, Pons JL, Dupuy B, et al.: **Cwp19 Is a Novel Lytic Transglycosylase Involved in Stationary-**
258 **Phase Autolysis Resulting in Toxin Release in *Clostridium difficile*.** *mBio* 2018, **9**.
- 259 27. Usenik A, Renko M, Mihelič M, Lindič N, Borišek J, Perdih A, Pretnar G, Müller U, Turk D: **The**
260 **CWB2 Cell Wall-Anchoring Module Is Revealed by the Crystal Structures of the *Clostridium***
261 ***difficile* Cell Wall Proteins Cwp8 and Cwp6.** *Structure* 2017, **25**:514-521.
- 262 28. Wu X, Paskaleva EE, Mehta KK, Dordick JS, Kane RS: **Wall Teichoic Acids Are Involved in the**
263 **Medium-Induced Loss of Function of the Autolysin CD11 against *Clostridium difficile*.** *Sci*
264 *Rep* 2016, **6**:35616.
- 265 29. ** Garcia-Garcia T, Poncet S, Cuenot E, Douché T, Giai Gianetto Q, Peltier J, Courtin P, Chapot-
266 Chartier MP, Matondo M, Dupuy B, et al.: **Ser/Thr Kinase-Dependent Phosphorylation of the**
267 **Peptidoglycan Hydrolase CwIA Controls Its Export and Modulates Cell Division in**
268 ***Clostridioides difficile*.** *mBio* 2021, **12**.
- 269 In this publication, a new type of regulation, based on protein phosphorylation by Ser/Thr Kinases is
270 highlighted. This regulation is involved in the bacterial cell shape and antibiotic resistance.
- 271

- 272 30. Zhu D, Patabendige H, Tomlinson BR, Wang S, Hussain S, Flores D, He Y, Shaw LN, Sun X: **Cwl0971,**
273 **a novel peptidoglycan hydrolase, plays pleiotropic roles in *Clostridioides difficile* R20291.**
274 *Environ Microbiol* 2021.
- 275 31. Desvaux M, Candela T, Serror P: **Surfaceome and Proteosurfaceome in Parietal Monoderm**
276 **Bacteria: Focus on Protein Cell-Surface Display.** *Front Microbiol* 2018, **9**:100.
- 277 32. Cuenot E, Garcia-Garcia T, Douche T, Gorgette O, Courtin P, Denis-Quanquin S, Hoys S, Tremblay
278 YDN, Matondo M, Chapot-Chartier MP, et al.: **The Ser/Thr Kinase PrkC Participates in Cell**
279 **Wall Homeostasis and Antimicrobial Resistance in *Clostridium difficile*.** *Infect Immun* 2019,
280 **87**.
- 281 33. ** Coullon H, Rifflet A, Wheeler R, Janoir C, Boneca IG, Candela T: **N-Deacetylases required for**
282 **muramic- δ -lactam production are involved in *Clostridium difficile* sporulation, germination,**
283 **and heat resistance.** *J Biol Chem* 2018, **293**:18040-18054.
- 284 This publication provides extensive characterization of *C. difficile* cortex using state-of-the-art
285 analyses, and establishes the role of PdaA and PdaB in the δ -lactam synthesis.
286
- 287 34. Popham DL, Helin J, Costello CE, Setlow P: **Analysis of the peptidoglycan structure of *Bacillus***
288 ***subtilis* endospores.** *J Bacteriol* 1996, **178**:6451-6458.
- 289 35. Orsburn B, Melville SB, Popham DL: **Factors contributing to heat resistance of *Clostridium***
290 ***perfringens* endospores.** *Appl Environ Microbiol* 2008, **74**:3328-3335.
- 291 36. Gilmore ME, Bandyopadhyay D, Dean AM, Linnstaedt SD, Popham DL: **Production of muramic**
292 **delta-lactam in *Bacillus subtilis* spore peptidoglycan.** *J Bacteriol* 2004, **186**:80-89.
- 293 37. **Diaz OR, Sayer CV, Popham DL, Shen A: ***Clostridium difficile* Lipoprotein GerS Is Required for**
294 **Cortex Modification and Thus Spore Germination.** *mSphere* 2018, **3**.
- 295 This publication analyzed the synthesis of δ -lactams in the spore cortex of *C. difficile* by GerS, CwLD
296 and PdaA
297
- 298 38. Fimlaid KA, Jensen O, Donnelly ML, Francis MB, Sorg JA, Shen A: **Identification of a Novel**
299 **Lipoprotein Regulator of *Clostridium difficile* Spore Germination.** *PLoS Pathog* 2015,
300 **11**:e1005239.
- 301 39. Popham DL, Helin J, Costello CE, Setlow P: **Muramic lactam in peptidoglycan of *Bacillus subtilis***
302 **spores is required for spore outgrowth but not for spore dehydration or heat resistance.**
303 *Proc Natl Acad Sci U S A* 1996, **93**:15405-15410.
- 304 40. Francis MB, Allen CA, Sorg JA: **Spore Cortex Hydrolysis Precedes Dipicolinic Acid Release during**
305 ***Clostridium difficile* Spore Germination.** *J Bacteriol* 2015, **197**:2276-2283.
- 306 41. Francis MB, Sorg JA: **Detecting Cortex Fragments During Bacterial Spore Germination.** *J Vis Exp*
307 2016.
- 308 42. Gutelius D, Hokeness K, Logan SM, Reid CW: **Functional analysis of SleC from *Clostridium***
309 ***difficile*: an essential lytic transglycosylase involved in spore germination.** *Microbiology*
310 *(Reading)* 2014, **160**:209-216.
- 311 43. Saujet L, Pereira FC, Serrano M, Soutourina O, Monot M, Shelyakin PV, Gelfand MS, Dupuy B,
312 Henriques AO, Martin-Verstraete I: **Genome-wide analysis of cell type-specific gene**
313 **transcription during spore formation in *Clostridium difficile*.** *PLoS Genet* 2013, **9**:e1003756.
- 314 44. Vasudevan P, Weaver A, Reichert ED, Linnstaedt SD, Popham DL: **Spore cortex formation in**
315 ***Bacillus subtilis* is regulated by accumulation of peptidoglycan precursors under the control**
316 **of sigma K.** *Mol Microbiol* 2007, **65**:1582-1594.
- 317 45. Dembek M, Kelly A, Barwinska-Sendra A, Tarrant E, Stanley WA, Vollmer D, Biboy J, Gray J,
318 Vollmer W, Salgado PS: **Peptidoglycan degradation machinery in *Clostridium difficile***
319 **forespore engulfment.** *Mol Microbiol* 2018, **110**:390-410.
- 320 46. Kelly A, Salgado PS: **The engulfosome in *C. difficile*: Variations on protein machineries.** *Anaerobe*
321 2019, **60**:102091.

322



324

325 Figure 1: Peptidoglycan and cortex structures

326 Peptidoglycan (A) and cortex (B) structures of *C. difficile* are presented. A minimal structure named
 327 muropeptide is represented in the right-hand side framed section of the figure. It is composed of two
 328 sugars, a muramic acid and a glucosamine, and a peptide which contains L-alanine (L-Ala), D-glutamate
 329 (D-Glu), 2,6 diaminopimelic acid (A₂pm) and D-Alanine (D-Ala) as represented. Peptidoglycan and
 330 cortex structures are represented here by assembling of typical muropeptides linked together, forming
 331 a chain of glycan. The principal modifications are indicated and highlighted by a colored box.

332

333